scholarly journals Pneumocystis jirovecii pneumonia as an initial manifestation of hyper-IgM syndrome in an infant

Medicine ◽  
2019 ◽  
Vol 98 (7) ◽  
pp. e14559 ◽  
Author(s):  
Danbi Kim ◽  
Ju Ae Shin ◽  
Seung Beom Han ◽  
Nack-Gyun Chung ◽  
Dae Chul Jeong
2020 ◽  
Vol 66 (6) ◽  
pp. 648-654
Author(s):  
Sai Hu Huang ◽  
Xiang Ying Meng ◽  
Zhen Jiang Bai ◽  
Ying Li ◽  
Shui Yan Wu

Abstract We reported a Chinese boy with X-linked hyper IgM (XHIGM) syndrome, manifesting as recurrent and severe pneumonia caused by Pneumocystis jirovecii. His parents were healthy and unrelated. In August 2018, the 5-month-old boy manifested as cough and dyspnea, and then in July 2019, he was admitted because of the same symptoms. Immunological results of the two admissions both showed low IgG, low IgA, normal IgM and high levels of 1,3-β-D-glucan (BDG). Using next-generation sequencing (NGS), great reading counts of P. jirovecii were identified from the deep sputum in both admissions. Caspofungin combined with trimethoprim-sulfamethoxazole were used to anti-infection, and he recovered quickly. Whole-exome sequencing was performed for this family because of immune suppression, the disease-causing gene (exon 10–22 of CD40L) deletion for XHIGM syndrome was identified. NGS is beneficial for etiology diagnosis. Pneumocystis jirovecii pneumonia as an opportunistic infection could be recurrent in patients with XHIGM syndrome.


2000 ◽  
Vol 159 (6) ◽  
pp. 453-455 ◽  
Author(s):  
Martin Benesch ◽  
Andreas Pfleger ◽  
Ernst Eber ◽  
Ulrike Orth ◽  
Maximilian S. Zach

1998 ◽  
Vol 18 (1) ◽  
pp. 71-78
Author(s):  
Michael Miller ◽  
Ilham Algayed ◽  
Ram Yogev ◽  
Pauline Chou ◽  
Paul Scholl ◽  
...  

2020 ◽  
pp. 107815522097904
Author(s):  
Monica Awad ◽  
Caroline M Sierra ◽  
Elhaam Mesghali ◽  
Khaled Bahjri

Current recommendations for prophylaxis of Pneumocystis jirovecii pneumonia in oncology patients include administration of trimethoprim/sulfamethoxazole (TMP/SMX) three times weekly or the same total weekly dose given daily. The primary objective of this study was to evaluate the efficacy of two consecutive days per week of TMP/SMX for prevention of Pneumocystis jirovecii pneumonia (PJP) in pediatric oncology patients. A retrospective cohort, single-center analysis was conducted in oncology patients 21 years and younger who received TMP/SMX for PJP prophylaxis between February 1, 2013 and July 31, 2017. Changes to the prophylaxis regimen were documented and analyzed. A total of 322 patients received TMP/SMX on two consecutive days per week for PJP prevention, of whom four had confirmed PJP (1.3%). Neutropenia was the most common reason for switching to alternative prophylaxis therapy (11.5%). Two consecutive prophylaxis days with TMP/SMX may be insufficient to prevent PJP in children with hematologic malignancies. Neutropenia remains a barrier for TMP/SMX use for PJP prophylaxis. Further studies to compare PJP incidence in children receiving alternative prophylaxis regimens should be considered.


Sign in / Sign up

Export Citation Format

Share Document